These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30687999)

  • 21. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
    van Dalen A; Favier J; Hallensleben E; Burges A; Stieber P; de Bruijn HW; Fink D; Ferrero A; McGing P; Harlozinska A; Kainz Ch; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R; Goike H
    Eur J Gynaecol Oncol; 2009; 30(6):609-15. PubMed ID: 20099488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
    Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
    J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H; Pradjatmo H
    Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
    Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
    Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
    Qin L; Huang H; Chen M; Liang Y; Wang H
    J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer.
    Li Y; Zhang C; Ji R; Lu H; Zhang W; Li LL; Liu R; Qian H; He A
    Int J Gynecol Cancer; 2020 Jan; 30(1):74-82. PubMed ID: 31822507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.
    Chang C; Chiang AJ; Wang HC; Chen WA; Chen J
    Ann Surg Oncol; 2015 Nov; 22(12):3976-80. PubMed ID: 25777089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
    Abu Hassaan SO
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer.
    Hall MR; Petruckevitch A; Pascoe J; Persic M; Tahir S; Morgan JS; Gourley C; Stuart N; Crawford SM; Kornbrot DE; Qian W; Rustin GJ
    Int J Gynecol Cancer; 2014 May; 24(4):676-81. PubMed ID: 24651630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.